Zacks: Brokerages Set $11.16 Target Price for DelMar Pharmaceuticals Inc (DMPI)

DelMar Pharmaceuticals Inc (NASDAQ:DMPI) has earned an average broker rating score of 1.50 (Buy) from the four analysts that cover the stock, Zacks Investment Research reports. One research analyst has rated the stock with a hold recommendation and three have assigned a strong buy recommendation to the company.

Brokers have set a 1-year consensus target price of $11.16 for the company and are forecasting that the company will post ($0.13) earnings per share for the current quarter, according to Zacks. Zacks has also assigned DelMar Pharmaceuticals an industry rank of 187 out of 265 based on the ratings given to its competitors.

Separately, HC Wainwright set a $12.00 price target on shares of DelMar Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, January 4th.

Shares of DelMar Pharmaceuticals (NASDAQ:DMPI) traded up $0.01 during trading on Monday, reaching $0.98. 440,100 shares of the company’s stock traded hands, compared to its average volume of 799,427. DelMar Pharmaceuticals has a twelve month low of $0.78 and a twelve month high of $5.20. The company has a market capitalization of $21.27, a price-to-earnings ratio of -1.35 and a beta of 1.22.

DelMar Pharmaceuticals (NASDAQ:DMPI) last announced its earnings results on Thursday, February 15th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.01. analysts expect that DelMar Pharmaceuticals will post -0.54 EPS for the current fiscal year.

An institutional investor recently bought a new position in DelMar Pharmaceuticals stock. Susquehanna International Group LLP purchased a new position in shares of DelMar Pharmaceuticals Inc (NASDAQ:DMPI) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 364,496 shares of the company’s stock, valued at approximately $306,000. Susquehanna International Group LLP owned approximately 1.69% of DelMar Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 16.94% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This article was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another publication, it was stolen and republished in violation of US and international copyright legislation. The legal version of this article can be viewed at

DelMar Pharmaceuticals Company Profile

DelMar Pharmaceuticals, Inc is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer.

Get a free copy of the Zacks research report on DelMar Pharmaceuticals (DMPI)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for DelMar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DelMar Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply